CD4 and colitis: To evaluate the therapeutic efficacy of dual-targeting EVs in vivo, we established a humanized colitis mouse model in which NSG mice were adoptively transferred with human PBMCs or CD4+ T cells, followed by induction of colitis using trinitrobenzene sulfonic acid (TNBS) (Supplementary Fig. 13a).